1. Scrip
  2. >>Business

Intellia To Take On Pfizer Blockbuster With Gene-Editing Therapy

Aims To Challenge Vyndaqel

 
• By Andrew McConaghie

After achieving a landmark in gene-editing with NTLA-2001, Intellia moves to expand its reach into a larger market.

Intellia HQ
It is still early days for its vivo gene-editing therapy NTLA-2001, but Intellia is accelerating its challenge Pfizer. • Source: Alamy

Intellia Therapeutics, Inc. has broadened a trial of its in vivo gene-editing candidate NTLA-2001 in order to take on Pfizer’s rare disease blockbusters Vyndaqel and Vyndamax.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Scrip

Merck & Co. CMO Barr On Breaking Into Immunology And Ophthalmology

 
• By Jessica Merrill

Chief medical officer Eliav Barr discussed Merck’s investment in new therapeutic areas and business development in an interview with Scrip.

Zelluna Believes Its TCR Tech Can Unlock Natural Killer Cell Potential

 
• By Andrew McConaghie

While CAR-NKs have pivoted towards autoimmune disease, the Norwegian biotech believes its unique platform can deliver in oncology

AstraZeneca COPD Drug Breztri Breezes Through Asthma Trials

 
• By Kevin Grogan

The triple therapy improves lung function in the Phase III KALOS and LOGOS studies